Yeyang Su speaks about the personal and relational aspects that are silent in China’s family-planning policy deliberations.
Vanessa Gruben argues that Ontario’s new IVF policy should take further steps to ensure the safety and well-being of women and children.
Matthew Herder and Trudo Lemmens explore the ways that Canada’s transparency legislation may limit researchers’ abilities to scrutinize drug safety and effectiveness.
Carolyn McLeod argues that the Ontario government should not contribute to the view that adoption is second best as a way of building families.
Miriam Zoll raises concerns about Intel’s employees’ fertility benefits.
